Abstract
Native SERPINs are currently the treatment of choice for diseases driven by excessive serine protease activity. Nonetheless, their lack of specificity and potency as well as the short half-life of their recombinant counterparts hamper their therapeutic application and cost-effectiveness. These limitations can be overcome by designing novel SERPIN variants with
... read more